X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11944) 11944
Publication (1540) 1540
Book Review (195) 195
Book Chapter (161) 161
Book / eBook (27) 27
Conference Proceeding (21) 21
Dissertation (5) 5
Data Set (2) 2
Magazine Article (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (8242) 8242
humans (4408) 4408
index medicus (4153) 4153
cyclic amp - metabolism (3535) 3535
male (3350) 3350
rats (3092) 3092
mice (2043) 2043
biochemistry & molecular biology (2033) 2033
cyclic gmp - metabolism (1918) 1918
female (1655) 1655
cell biology (1631) 1631
pharmacology & pharmacy (1599) 1599
signal transduction (1557) 1557
phosphodiesterase inhibitors - pharmacology (1513) 1513
neurosciences (1496) 1496
camp (1487) 1487
cells, cultured (1482) 1482
phosphorylation (1262) 1262
cyclic amp (1248) 1248
phosphodiesterase (1212) 1212
3',5'-cyclic-amp phosphodiesterases - metabolism (1131) 1131
in vitro techniques (1080) 1080
proteins (1051) 1051
expression (1021) 1021
kinetics (989) 989
cyclic amp-dependent protein kinases - metabolism (962) 962
dose-response relationship, drug (955) 955
cyclic-amp (950) 950
physiology (905) 905
phosphoric diester hydrolases - metabolism (883) 883
activation (848) 848
nitric oxide (840) 840
rats, sprague-dawley (823) 823
cgmp (820) 820
adenylyl cyclases - metabolism (797) 797
calcium - metabolism (790) 790
physiological aspects (774) 774
article (769) 769
dependent protein-kinase (763) 763
cell line (750) 750
analysis (748) 748
cyclic nucleotide phosphodiesterases, type 4 (738) 738
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (733) 733
cells (704) 704
gene expression (700) 700
molecular sequence data (697) 697
nitric-oxide (688) 688
enzyme inhibitors - pharmacology (681) 681
research (670) 670
colforsin - pharmacology (650) 650
endocrinology & metabolism (647) 647
signal transduction - physiology (645) 645
kinases (623) 623
time factors (623) 623
cyclic amp - pharmacology (611) 611
cyclic gmp (610) 610
research article (607) 607
signal transduction - drug effects (607) 607
multidisciplinary sciences (591) 591
rats, wistar (590) 590
amino acid sequence (585) 585
cyclic amp - physiology (584) 584
enzymes (570) 570
1-methyl-3-isobutylxanthine - pharmacology (569) 569
inhibition (566) 566
calcium (562) 562
nitric oxide - metabolism (558) 558
cyclic adenylic acid (544) 544
protein binding (523) 523
cyclic-nucleotide phosphodiesterases (514) 514
mice, inbred c57bl (493) 493
enzyme activation (489) 489
cattle (484) 484
cyclic gmp - analogs & derivatives (483) 483
rolipram (480) 480
mutation (470) 470
cyclic nucleotide phosphodiesterases, type 5 (467) 467
gene-expression (461) 461
cyclic nucleotide phosphodiesterases, type 4 - metabolism (460) 460
cyclic-gmp (459) 459
disease models, animal (456) 456
microbiology (451) 451
isoproterenol - pharmacology (448) 448
in-vitro (447) 447
guanylate cyclase - metabolism (445) 445
medicine (440) 440
rodents (439) 439
nitric-oxide synthase (429) 429
phosphodiesterases (425) 425
sildenafil citrate (425) 425
brain (421) 421
protein kinases (421) 421
biology (420) 420
rna, messenger - metabolism (420) 420
adult (419) 419
isoenzymes - metabolism (416) 416
cyclic gmp - pharmacology (405) 405
cyclic nucleotide phosphodiesterases, type 5 - metabolism (401) 401
protein kinase a (399) 399
cyclic-nucleotide phosphodiesterase (397) 397
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (18) 18
UofT at Mississauga - Stacks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Gerstein Science - Periodical Stacks (1) 1
Online Resources - Online (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11935) 11935
Russian (18) 18
German (13) 13
Chinese (12) 12
Japanese (7) 7
French (4) 4
Dutch (2) 2
Portuguese (2) 2
Spanish (2) 2
Bulgarian (1) 1
Italian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2008, Volume 105, Issue 49, pp. 19532 - 19537
Cyclic nucleotide phosphodiesterase (PDE) isoforms can influence disease pathogenesis and be novel therapeutic targets. Because lower cAMP levels may... 
Protein isoforms | T lymphocytes | Chronic lymphocytic leukemia | Messenger RNA | Cyclic nucleotides | B lymphocytes | Medical treatment | Apoptosis | Vehicles | B cell leukemia | B cell | Survivin | cAMP | survivin | CELLS | CAMP-SPECIFIC PHOSPHODIESTERASE | AMP | INHIBITOR-INDUCED APOPTOSIS | PROTEIN-KINASE | MULTIDISCIPLINARY SCIENCES | apoptosis | HUMAN B-LYMPHOCYTES | THEOPHYLLINE | PATHWAY | THERAPEUTIC TARGET | GENE-EXPRESSION | Cyclic Nucleotide Phosphodiesterases, Type 3 - genetics | Cyclic Nucleotide Phosphodiesterases, Type 4 | Humans | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | RNA, Messenger - metabolism | Enzyme Activation - immunology | Cell Division - immunology | Cyclic Nucleotide Phosphodiesterases, Type 7 - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - physiopathology | Membrane Potential, Mitochondrial | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Cyclic AMP-Dependent Protein Kinases - metabolism | 3',5'-Cyclic-AMP Phosphodiesterases - metabolism | B-Lymphocytes - cytology | B-Lymphocytes - enzymology | Phosphodiesterase 3 Inhibitors | Cells, Cultured | Cyclic Nucleotide Phosphodiesterases, Type 7 - metabolism | Phosphodiesterase Inhibitors - pharmacology | 3',5'-Cyclic-AMP Phosphodiesterases - genetics | Gene Expression Regulation, Leukemic | Gene Expression Regulation, Enzymologic | Apoptosis - immunology | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Cyclic Nucleotide Phosphodiesterases, Type 7 - antagonists & inhibitors | Physiological aspects | Genetic aspects | Cyclic adenylic acid | Research | Drug therapy | Phosphodiesterases | Biological Sciences
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 08/2011, Volume 54, Issue 15, pp. 5607 - 5611
Journal Article
Cancer Cell, ISSN 1535-6108, 2011, Volume 19, Issue 1, pp. 45 - 57
We show that in melanoma cells oncogenic BRAF, acting through MEK and the transcription factor BRN2, downregulates the cGMP-specific phosphodiesterase PDE5A.... 
APOPTOSIS | SMOOTH-MUSCLE | ACTIVATION | CYCLIC-GMP | CANCER CELLS | GENE | ONCOLOGY | INHIBITS GROWTH | PROLIFERATION | B-RAF | EXPRESSION | CELL BIOLOGY | Cyclic GMP - pharmacology | RNA, Small Interfering - genetics | Protein Binding - genetics | Cell Proliferation | Gene Expression - drug effects | Calcium - metabolism | Gene Expression - genetics | Homeodomain Proteins - metabolism | Humans | Neoplasm Invasiveness - prevention & control | Lung Neoplasms - pathology | Promoter Regions, Genetic - genetics | Cell Movement - genetics | Heterocyclic Compounds, 4 or More Rings - pharmacology | Calcium - antagonists & inhibitors | Myosin Light Chains - antagonists & inhibitors | Cyclic GMP - analogs & derivatives | Lung Neoplasms - secondary | Neoplasm Invasiveness - pathology | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Phosphodiesterase 5 Inhibitors - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Gene Expression Regulation, Neoplastic - physiology | Cardiac Myosins - metabolism | Proto-Oncogene Proteins B-raf - metabolism | Cardiac Myosins - antagonists & inhibitors | POU Domain Factors - metabolism | Melanoma - metabolism | Melanoma - pathology | Calcimycin - pharmacology | Down-Regulation - genetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Cell Movement - drug effects | Animals | Cyclic GMP - metabolism | Lung Neoplasms - prevention & control | Mice, Nude | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Transplantation, Heterologous - pathology | Mice | Myosin Light Chains - metabolism | Protein Kinase Inhibitors - pharmacology
Journal Article
Circulation, ISSN 0009-7322, 04/2010, Volume 121, Issue 13, pp. 1474 - 1483
Background-Phosphodiesterase type 5 (PDE5) inhibition has been shown to exert profound beneficial effects in the failing heart, suggesting a significant role... 
Heart failure | Cyclic nucleotide phosphodiesterases | Oxidative stress | Type 5 | heart failure | PRESSURE-OVERLOAD | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | ENDOTHELIAL DYSFUNCTION | NITRIC-OXIDE SYNTHASE | SYSTOLIC OVERLOAD | XANTHINE-OXIDASE | INHIBITION | CARDIAC-HYPERTROPHY | cyclic nucleotide phosphodiesterases, type 5 | PERIPHERAL VASCULAR DISEASE | RAT-HEART | HEMATOLOGY | EXTRACELLULAR-SUPEROXIDE DISMUTASE | oxidative stress | Phosphorylation - physiology | Superoxide Dismutase - genetics | Humans | Oxidative Stress - physiology | Heart Failure - physiopathology | Phosphodiesterase 5 Inhibitors | Male | Extracellular Signal-Regulated MAP Kinases - metabolism | Sulfones - pharmacology | Cyclic GMP-Dependent Protein Kinases - metabolism | Myocytes, Cardiac - enzymology | Sildenafil Citrate | Hypertrophy, Left Ventricular - drug therapy | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Superoxide Dismutase - metabolism | Disease Models, Animal | Purines - pharmacology | Hypertrophy, Left Ventricular - metabolism | Mice, Inbred C57BL | Phosphodiesterase Inhibitors - pharmacology | Heart Failure - metabolism | Antioxidants - pharmacology | Piperazines - pharmacology | Heart Failure - drug therapy | Mice, Knockout | Animals | Nitric Oxide Synthase Type II - genetics | Signal Transduction - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Signal Transduction - physiology | Mice | Hypertrophy, Left Ventricular - physiopathology | Oxidative Stress - drug effects | Organometallic Compounds - pharmacology | Nitric Oxide Synthase Type II - metabolism | Heart | Heart ventricle, Left | Physiological aspects | Genetic aspects | Research | Gene expression | PDE5
Journal Article
Neuropharmacology, ISSN 0028-3908, 01/2013, Volume 64, pp. 114 - 123
Previous studies have demonstrated that cognitive function can be restored in mouse models of Alzheimer's disease (AD) following administration of sildenafil,... 
PDE5 | Tadalafil | Alzheimer's disease | Memory | Blood–brain barrier | Blood-brain barrier | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | ALZHEIMERS-DISEASE | MEMORY DEFICITS | GLYCOGEN-SYNTHASE KINASE-3 | CGMP-BINDING | NEUROSCIENCES | INHIBITION | MESSENGER-RNA | NITRIC-OXIDE | GMP PATHWAY | OBJECT RECOGNITION | PHARMACOLOGY & PHARMACY | Gene Expression Regulation, Enzymologic - drug effects | Sulfones - therapeutic use | Species Specificity | Nootropic Agents - metabolism | Humans | Half-Life | Macaca fascicularis | Male | Carbolines - metabolism | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Brain - metabolism | Sildenafil Citrate | Tissue Distribution | Cognition Disorders - prevention & control | Cognition Disorders - etiology | Phosphodiesterase 5 Inhibitors - metabolism | Female | Phosphodiesterase 5 Inhibitors - therapeutic use | Purines - therapeutic use | Carbolines - blood | Carbolines - therapeutic use | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Disease Models, Animal | Phosphodiesterase 5 Inhibitors - blood | Mice, Inbred C57BL | Nootropic Agents - pharmacokinetics | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Mice, Transgenic | Piperazines - therapeutic use | Nootropic Agents - blood | Blood-Brain Barrier - metabolism | Brain - drug effects | Animals | Alzheimer Disease - metabolism | Brain - pathology | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Mice | Carbolines - pharmacokinetics | Alzheimer Disease - genetics | Neurosciences | Messenger RNA | Analysis | Smart drugs and nutrients | Universities and colleges
Journal Article
Circulation, ISSN 0009-7322, 05/2012, Volume 125, Issue 19, pp. 2323 - 2333
Background-cGMP phosphodiesterase type 5 protein is upregulated in myocardial hypertrophy. However, it has never been ascertained whether phosphodiesterase... 
fibrosis | phosphodiesterase inhibitors heart failure | diabetes mellitus type 2 | cardiac magnetic resonance imaging | diabetic diastolic heart failure | CARDIAC & CARDIOVASCULAR SYSTEMS | PULMONARY-HYPERTENSION | ENDOTHELIAL DYSFUNCTION | SILDENAFIL CITRATE | AORTIC-STENOSIS | DIASTOLIC HEART-FAILURE | HYPERTROPHY | FLOW-MEDIATED DILATATION | NITRIC-OXIDE | VALVE-REPLACEMENT | PERIPHERAL VASCULAR DISEASE | TYPE-5 INHIBITION | Piperazines - administration & dosage | Diabetic Cardiomyopathies - drug therapy | Follow-Up Studies | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Sulfones - adverse effects | Magnetic Resonance Imaging - methods | Male | Purines - administration & dosage | Torsion, Mechanical | Sildenafil Citrate | Hypertrophy, Left Ventricular - pathology | Purines - adverse effects | Cardiac Imaging Techniques - methods | Hypertrophy, Left Ventricular - drug therapy | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Diabetes Mellitus, Type 2 - complications | Phosphodiesterase 5 Inhibitors - administration & dosage | Treatment Outcome | Piperazines - adverse effects | Diabetic Cardiomyopathies - pathology | Aged | Ventricular Remodeling - drug effects | Sulfones - administration & dosage | Care and treatment | Magnetic resonance imaging | Cardiomyopathy | Clinical trials | Diagnosis | Phosphodiesterases | Heart diseases | Health aspects | Methods
Journal Article
Cardiovascular Research, ISSN 0008-6363, 06/2015, Volume 106, Issue 3, pp. 408 - 420
Journal Article
Clinical Science, ISSN 0143-5221, 12/2015, Volume 129, Issue 12, pp. 1061 - 1075
Reduced nitric oxide (NO)/cGMP signalling is observed in age-related vascular disease. We hypothesize that this disturbed signalling involves effects of... 
Vascular disease | Aging | Blood pressure | Genetic association | Phosphodiesterases | MEDICINE, RESEARCH & EXPERIMENTAL | blood pressure | OXIDATIVE-STRESS | ENDOTHELIAL DYSFUNCTION | genetic association | ATHEROSCLEROSIS | BLOOD-PRESSURE | ARTERIAL | vascular disease | DISEASE | phosphodiesterases | NITRIC-OXIDE | VINPOCETINE | aging | CONGESTIVE-HEART-FAILURE | ASSOCIATION | Blood Pressure | Endonucleases - deficiency | Endonucleases - genetics | Humans | Hyperplasia | Gene Expression Regulation, Neoplastic | DNA-Binding Proteins - deficiency | Dose-Response Relationship, Drug | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Aging - genetics | Carotid Artery Diseases - pathology | Cellular Senescence | Carotid Arteries - enzymology | Hypertension - enzymology | Hypertension - genetics | Myocytes, Smooth Muscle - drug effects | Phosphodiesterase 5 Inhibitors - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Second Messenger Systems | Muscle, Smooth, Vascular - drug effects | Genetic Predisposition to Disease | Genome-Wide Association Study | Vasodilator Agents - pharmacology | Carotid Intima-Media Thickness | Myocytes, Smooth Muscle - enzymology | Mice, Inbred C57BL | Cells, Cultured | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | DNA-Binding Proteins - genetics | Hypertension - physiopathology | Mice, Knockout | Hydrolysis | Phenotype | Animals | Cyclic GMP - metabolism | Carotid Artery Diseases - enzymology | Carotid Artery Diseases - genetics | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Carotid Arteries - pathology | Polymorphism, Single Nucleotide | Vasodilation - drug effects | In Vitro Techniques | Cyclic Nucleotide Phosphodiesterases, Type 1 - genetics | Muscle, Smooth, Vascular - enzymology | Aging - metabolism
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 04/2010, Volume 285, Issue 17, pp. 13244 - 13253
Activation of Ca(2+) signaling induced by receptor stimulation and mechanical stress plays a critical role in the development of cardiac hypertrophy. A... 
Protein Kinase C - genetics | Phosphodiesterase Inhibitors - adverse effects | Calcium - metabolism | Humans | Phosphodiesterase 5 Inhibitors | Sulfones - adverse effects | Male | Mutation, Missense | Sulfones - pharmacology | Cyclic GMP-Dependent Protein Kinases - metabolism | Cyclic GMP-Dependent Protein Kinases - genetics | Gene Knockdown Techniques | Sildenafil Citrate | Diglycerides - metabolism | Protein Kinase C - metabolism | Potassium Chloride - pharmacology | Purines - adverse effects | GTP-Binding Protein alpha Subunits, Gq-G11 - metabolism | TRPC Cation Channels - genetics | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Calcium Signaling | Cell Line | GTP-Binding Protein alpha Subunits, Gq-G11 - genetics | Purines - pharmacology | Phosphodiesterase Inhibitors - pharmacology | Rats | Enzyme Activation - drug effects | Piperazines - adverse effects | Piperazines - pharmacology | Animals | Cardiomegaly - prevention & control | TRPC Cation Channels - metabolism | Cardiomegaly - chemically induced | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Myocytes, Cardiac - metabolism | Diglycerides - genetics | Mice | Cardiomegaly - genetics | Enzyme Activation - genetics | Amino Acid Substitution | Cardiomegaly - metabolism | Index Medicus | Phosphorylation | Signal Transduction | Calcium | TRPC Channel | Cyclic Nucleotides | Channels | Cell Biology | Protein Kinases | Cyclic GMP | Cyclic Nucleotide | Membrane | Phosphodiesterases | Cardiac Hypertrophy
Journal Article
The Journal of Sexual Medicine, ISSN 1743-6095, 10/2011, Volume 8, Issue 10, pp. 2746 - 2760
In humans, prostate phosphodiesterase type 5 inhibitors (PDE5) expression was prominently localized in the endothelial and smooth muscle cells of the vascular... 
Human Vesicular‐Deferential Artery | Prostate Oxygenation | PDE5 Inhibition | Hypoxyprobe | Prostate oxygenation | PDE5 inhibition | Human vesicular-deferential artery | SYMPTOMS SECONDARY | FUNCTIONAL-ACTIVITY | VAS-DEFERENS | NITRIC-OXIDE SYNTHASE | CHRONIC ISCHEMIA | BLOOD-FLOW | CAVERNOUS NEUROTOMY | IMPROVES ERECTILE FUNCTION | HUMAN DEFERENTIAL ARTERY | Human Vesicular-Deferential Artery | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | Muscle, Smooth, Vascular - metabolism | Humans | Rats, Inbred WKY | Male | Nitroprusside - pharmacology | Oxygen - metabolism | Prostate - metabolism | Urinary Tract - enzymology | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Prostate - drug effects | Urinary Tract - metabolism | Phosphodiesterase 5 Inhibitors - pharmacology | Urinary Bladder - enzymology | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Real-Time Polymerase Chain Reaction | Muscle, Smooth, Vascular - drug effects | Rats, Inbred SHR | Urinary Bladder - metabolism | Endothelin-1 - metabolism | Rats | Tadalafil | Animals | Urinary Tract - blood supply | Urinary Bladder - blood supply | Muscle, Smooth, Vascular - enzymology | Urinary Tract - drug effects | Carbolines - pharmacology | Immunohistochemistry | Hypertension | Messenger RNA | Sodium nitroferricyanide | Cyanides | Cyclic guanylic acid | Endothelium
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 10/2016, Volume 59, Issue 19, pp. 8967 - 9004
Journal Article